

Immunomodulatory Effects of Stereotactic Body Radiation Therapy

Ariel E. Marciscano, MD
Assistant Attending, Department of Radiation Oncology




Financial Relationships

No relevant financial relationship(s) exist







GEISINGER
100
 "Make it the Best"
 Abigail Geisinger
 1827-1921
 "Geisinger Quality – Striving for Perfection"

I am not Dr. Marciscano!
 But I can at least try to
 show some implications of
 Immunomodulatory Effects
 in the models for SBRT

Jimm Grimm, PhD

AAPM 2019
San Antonio


Conflict of Interest

Dr. Grimm designed and holds intellectual property rights to the

DVH Evaluator software tool

(www.DiversiLabs.com) which is an FDA-cleared product in commercial use, and which has been used for this analysis

Funding from Accuray, NovoCure



FDA 510k Number K092928 Rx Only US Patents 9,019,307 & 9,192,782
 www.DiversiLabs.com service@DiversiLabs.com
 Soli Deo Gloria

GEISINGER
 MEDICINE EDUCATION

HyTIC Vision Papers, Jimm Grimm, PhD 5

What about the SAMs Questions?

- At least I will be able to show you a picture explaining that immunogenic cell death potentially includes the following molecular events: translocation of calreticulin, release of high mobility group box 1 (HMGB1) from the nucleus, and extracellular passive secretion of adenosine triphosphate (ATP)
- And at least I will be able to explain that the abscopal effect is not just a bystander effect, and is not only observed in preclinical models, and does not happen only from immunotherapy

GEISINGER
 MEDICINE EDUCATION


HyTIC Vision Papers, Jimm Grimm, PhD 6

HyTEC Vision Paper

Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities

Ariel E. Marciscano, MD,* Adriana Haimovitz-Friedman, PhD,* Percy Lee, MD,¹ Phuoc T. Tran, MD, PhD,¹ Wolfgang A. Tomé, PhD,² Chandan Guha, MD, PhD,³ Feng-Ming (Spring) Kong, MD, PhD,⁴ Arjun Sahgal, MD,⁵ Issam El Naqa, PhD,⁶ Andreas Rimmer, MD,⁷ Lawrence B. Marks, MD,** Silvia C. Formenti, MD,¹ and Theodore L. DeWeese, MD

Can SBRT trigger the body's immune system? (SAMs question)



Aorta and Major Vessel Dose Tolerance

- Aorta and Major Vessels are among the most radioresistant structures in the body
- For conventionally fractionated treatments we usually don't even contour them
- Then how can vascular damage be true?

A Single Endothelial Cell




Figure 22-23 Capillaries

(A) Electron micrograph of a cross section of a small capillary in the pancreas. The wall is formed by a single endothelial cell surrounded by a basal lamina.

- The smallest capillaries consist of a single endothelial cell
- wrapped around to touch itself
- Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002

Think Small

- If you want to understand
 - Vascular Damage
 - Immunomodulatory Effects
- You need to think small:
 - Like a single photon...
 - Like a single cell...

Think Small

- Think about a single blood cell
- squeezing through a capillary
- that consists of
- a single endothelial cell



Image from SciencePhotoLibrary

Think Small

- Think about radiation damage
- to the single endothelial cell
- causing leaky blood vessels




Image from SciencePhotoLibrary

HyTDC Vision Papers, James Geisinger, PhD

GEISINGER
MEDICINE EDUCATION

13

Little Things Are Big! - Yogi Berra



- A single endothelial cell can supply blood to about 3000 tumor cells

• J. Denekamp, Acta Radiologica Oncol, 23, p217, 1984


• C. Song, Rad Res, 177, p323, 2012

HyTDC Vision Papers, James Geisinger, PhD


GEISINGER
MEDICINE EDUCATION

14

Can SBRT trigger the body's immune system? (SAMs question)



RT Exposure/Release of Tumor-Associated Antigens (TAAs)




- SBRT promotes TAA release leading to antigen uptake/processing by DCs/APCs
- DCs then migrate to the DLN to cross-present TAA to naive T-cells



Sharabi AB et al. *Lancet Oncol* 2015


Anti cancer Effects of SBRT/SRS

- HyTEC Vision Paper:
- Secondary Cell Death
- C. Song et al.



Immunomodulatory Effects of SBRT: Abscopal Effect

Preclinical evidence has led to the intriguing hypothesis that local tumor irradiation can potentiate a systemic immune response – this includes the potential for regression of metastatic cancer outside of the irradiated field (abscopus) known as the **abscopal effect**, potentially mediated by CD8 T-cells recognizing neoantigens upregulated by radiation.



Clinical Experience supports that the abscopal effect is real but EXCEPTIONALLY rare

- how to consistently elicit this phenomenon is currently unknown

The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Poole's Gold or El Dorado?
 B. Xing¹, S. Sw¹, G.G. Hanna¹
¹Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19106

NEJM report of melanoma pt @ MSK on ipilimumab (anti-CTLA4) with POD that underwent SBRT 28.5Gy in 3 fx over 7 days to a paraspinal mass with 6MV photon coplanar 6-field IG-IMRT.

Near complete regression of disease after SBRT while continuing on ipilimumab



Pastow M et al. *NEJM* 2012

If these are true, why still use LQ?


- Vascular Damage
 - Immunomodulatory Effects
 - Stem Cell Effects
- Why do we still use LQ?
 - 1) It's the only model with 1000+ citations and data
 - 2) It still works reasonably well if you are careful
 - 3) We are still very interested in advanced models

HyTEC Vision Papers, James Geisinger, PhD

GEISINGER
RADIATION ONCOLOGY

19


Medium-to-Large Tumors, Physical Dose Fractionation Comparison: 2-Year Local Control



- Each dot is a stratified dose-fractionation-size group from the literature search
- Area of circle is proportional to number of patients in the study
- Logistic model, maximum-likelihood parameter fitting, profile likelihood 95% confidence intervals
- Physical dose in each fractionation, no biological effective dose (BED) model needed

HyTEC Central Metastases TCP

Medium-to-Large Tumors, Physical Dose Fractionation Comparison: 2-Year Local Control



- For medium-to-large sized tumors, the dose required to achieve 75% local control at 2 years was 22.6Gy in 1 fraction, 22.9Gy in 3 fractions, or 31.1Gy in 5 fractions.
- The α/β required to equate 25.6Gy/1fx with 31.1Gy/5fx is much larger than 20 Gy (36 Gy), but that seems abnormally high, so in the following models, a **more conservative $\alpha/\beta=20$ Gy** was used

HyTEC Central Metastases TCP

If these are true, why still use LQ?

- Vascular Damage
- Immunomodulatory Effects
- Stem Cell Effects

• Why do we still use LQ?

- 1) It's the only model with 1000+ citations and data
- 2) It still works reasonably well if you are careful
- 3) We are still very interested in advanced models
